Despite government efforts to prop up biopharma and med-tech research toward creating women’s health products, companies must eventually reach out to the private markets to bring their inventions to ...

Many studies have linked the presence of specific bacteria to various diseases. But a general overgrowth of gut bacteria can be a symptom of different conditions, including colorectal cancer and ...

President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. as U.S. Secretary of Health and Human Services (HHS) grabbed headlines globally, but the political jostling to come will determine ...

Merck & Co. Inc. has in-licensed Lanova Medicines Ltd.’s PD-1/VEGF bispecific antibody LM-299 in a deal worth up to $2.7 billion in a move to bolster its Keytruda (pembrolizumab) fortress. Under terms ...

Med-tech companies raised $7.35 billion in the third quarter of 2024, slightly down from $7.49 billion in the second quarter but up from $6.45 billion in Q1. Through the first three quarters of the ...

Celltrion Inc. said it would acquire Iqone Healthcare Switzerland SA in the fourth quarter of 2024 for about ₩30 billion (US$21.34 million) to expand its European business. “This move represents a ...

Vitalli Bio Inc. terminated a potential $477 million licensing deal for autoimmune disease drug, DWP-213388, signed a year ago with Daewoong Pharmaceutical Co. Ltd., although Vitalli still retains ...

Artificial intelligence-powered rare disease diagnostics firm 3billion Inc. debuted on the tech-heavy Kosdaq board of the Korea Exchange Nov. 14 with its IPO raising about ₩14.4 billion (US$10.25 ...

Poseida Therapeutics Inc. has updated progress made in its early-stage pipeline of differentiated T stem cell memory cell-rich allogeneic CAR T therapies in oncology and autoimmune diseases.

EA Pharma Co. Ltd. has described 2-amino-3-carboxymuconate-6-semialdehyde decarboxylase (ACMSD) inhibitors reported to be useful for the treatment of age-related issues, as well as inflammatory, ...

At the recent SITC meeting in Houston, Teva Pharmaceutical Industries Ltd. reported preclinical data for the fusion protein TEV-56278, which is in phase I development.

Copyright ©2024. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Manage cookie preferences ...